pyrazines has been researched along with topotecan in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (12.50) | 29.6817 |
2010's | 6 (75.00) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
Authors | Studies |
---|---|
Beretta, GL; Brigliadori, G; Corna, E; De Cesare, M; Fabbri, F; Ricotti, L; Rosetti, M; Supino, R; Tesei, A; Ulivi, P; Zoli, W; Zunino, F | 1 |
Kurzrock, R; Subbiah, V; Trent, JC | 1 |
Badgett, TC; Chen, QR; Cheuk, AT; Khan, J; Song, YK; Tsang, PS; Wei, JS | 1 |
Downward, J; Hancock, DC; Howell, M; Kelly, G; Kuznetsov, H; Marani, M; Molina-Arcas, M; Saunders, B; Steckel, M; Warne, PH; Weigelt, B | 1 |
Flatten, KS; Huehls, AM; Huntoon, CJ; Karnitz, LM; Kaufmann, SH; Sutor, SL; Wahner Hendrickson, AE | 1 |
Barnes, CS; Charlton, P; Doroshow, JH; Guha, R; Jones, J; Jossé, R; Martin, SE; Morris, J; Ormanoglu, P; Pfister, TD; Pollard, JR; Pommier, Y; Reaper, PM | 1 |
Allen, JW; Gandara, DR; Gitlitz, BJ; Kelly, K; Lara, PN; Mack, PC; Moon, J; Redman, MW; Semrad, TJ | 1 |
Elloumi, F; Jo, U; Kim, SH; Murai, Y; Pommier, Y; Rajapakse, VN; Saha, LK; Schultz, CW; Senatorov, IS; Takahashi, N; Thomas, A; Zenke, FT; Zimmermann, A | 1 |
1 trial(s) available for pyrazines and topotecan
Article | Year |
---|---|
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Recurrence; Small Cell Lung Carcinoma; Sorafenib; Topotecan; Young Adult | 2015 |
7 other study(ies) available for pyrazines and topotecan
Article | Year |
---|---|
Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Camptothecin; Disease Models, Animal; DNA Topoisomerases, Type I; Down-Regulation; Female; Humans; Mice; Mice, Nude; Protease Inhibitors; Pyrazines; RNA, Messenger; S Phase; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2005 |
Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Intracellular Signaling Peptides and Proteins; Middle Aged; Perivascular Epithelioid Cell Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Retroperitoneal Neoplasms; Sirolimus; Topotecan; TOR Serine-Threonine Kinases; Treatment Failure | 2010 |
Synthetic lethal screen identifies NF-κB as a target for combination therapy with topotecan for patients with neuroblastoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Mice; Mice, SCID; Microarray Analysis; Neuroblastoma; NF-kappa B; Pyrazines; RNA, Small Interfering; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2012 |
Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.
Topics: Alleles; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Colonic Neoplasms; Deoxycytidine; DNA Topoisomerases, Type I; GATA2 Transcription Factor; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Mutation; Nuclear Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; ras Proteins; RNA Interference; RNA, Small Interfering; Topoisomerase I Inhibitors; Topotecan; Transcriptional Activation | 2012 |
ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; cdc25 Phosphatases; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Immunoblotting; Ovarian Neoplasms; Phosphorylation; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Kinases; Protein Serine-Threonine Kinases; Pyrazines; Pyrazoles; Pyrimidines; RNA Interference; Signal Transduction; Sulfones; Topotecan | 2013 |
ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
Topics: Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; DNA Replication; DNA Topoisomerases, Type I; Histones; HT29 Cells; Humans; Irinotecan; Organothiophosphorus Compounds; Phosphorylation; Protein Kinases; Pyrazines; Replication Origin; Single-Cell Analysis; Sulfones; Topoisomerase I Inhibitors; Topotecan | 2014 |
Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Proliferation; Deoxycytidine; DNA Replication; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Isoxazoles; Lung Neoplasms; Mice; Mice, Nude; Morpholines; Pyrazines; Pyrazoles; Small Cell Lung Carcinoma; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |